Adaptive radiotherapy in locally advanced head and neck cancer: The importance of reduced margins
Physics and Imaging in Radiation Oncology · 2025-01 · 33 · 100696
DOI: 10.1016/j.phro.2025.100696 ↗Kurz gefasst
Fachartikel in der Zeitschrift Physics and Imaging in Radiation Oncology, 2025-01. Verfasst von Hedda Enocson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medical Radiation Physics, Department of Clinical Sciences Lund, Lund University, Lund, Sweden. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Accuray Inc, Mrs Berta Kamprad foundation for exploration and combat cancer, Swedish Foundation for Strategic Research.
Abstract (Originalsprache)
Background and Purpose: Adaptive radiotherapy (ART) involves treatment re-planning based on anatomical changes, which may improve target coverage and sparing of organs-at-risk (OARs). This study retrospectively assessed the technical feasibility and potential benefits of daily ART in combination with reduced planning target volume (PTV) margins for head and neck squamous cell carcinoma (HNSCC). Materials and Methods: Thirty-one patients, encompassing 902 treatment fractions, treated with radiotherapy to 60.0-68.0 Gy in 2 Gy/fraction were studied. Synthetic CTs (sCT) from daily kVCT images were created and contours propagated using deformable image registration (DIR). Target contours were reviewed and corrected. On the sCT, non-adapted delivered doses and ART-plans with 5 mm (clinical standard) and 2 mm PTV-margin were evaluated. All daily dose distributions were then accumulated.
Results
Target contours required correction in 48 % of the fractions. Daily non-adapted D98%,CTV was > 95 % in 890 (5 mm) and 825 (2 mm) out of 902 fractions. All adapted plans achieved D98%,CTV > 95 %. Significant reductions in mean doses to OARs were observed for PTV = 2 mm ART-plans: 4.1 Gy for parotid, 2.6 Gy for submandibular, 3.3 Gy for oral cavity, 4.0 Gy for esophagus, and 3.8 Gy for larynx.
Conclusion
ART-planning on sCT and DIR propagated contours was feasible and promising for further clinical testing. To obtain a potential clinical benefit of ART, a synchronous reduction of the PTV-margin was warranted. Daily ART can be used to maintain adequate target dosimetry for every fraction, though for the accumulated treatment, insufficient target coverage without ART is unlikely to occur.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Radiation Physics, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
- Radiation Physics, Department of Hematology, Oncology, and Radiation Physics, Skåne University Hospital, Sweden.
- Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
- Oncology, Department of Hematology, Oncology, and Radiation Physics, Skåne University Hospital, Sweden.
Förderung
- Accuray Inc
- Mrs Berta Kamprad foundation for exploration and combat cancer
- Swedish Foundation for Strategic Research
Zitieren
APA
Enocson, H., Haraldsson, A., Engström, P., Ceberg, S., Gebre-Medhin, M., Adrian, G., & Af Rosenschöld, P. M. (2025). Adaptive radiotherapy in locally advanced head and neck cancer: The importance of reduced margins. Physics and Imaging in Radiation Oncology, 33, 100696. https://doi.org/10.1016/j.phro.2025.100696
Vancouver
Enocson H, Haraldsson A, Engström P, Ceberg S, Gebre-Medhin M, Adrian G, et al. Adaptive radiotherapy in locally advanced head and neck cancer: The importance of reduced margins. Physics and Imaging in Radiation Oncology. 2025;33:100696. doi:10.1016/j.phro.2025.100696
BibTeX
@article{Enocson2025,
author = {Enocson, Hedda and Haraldsson, André and Engström, Per and Ceberg, Sofie and Gebre-Medhin, Maria and Adrian, Gabriel and Af Rosenschöld, Per Munck},
title = {Adaptive radiotherapy in locally advanced head and neck cancer: The importance of reduced margins},
journal = {Physics and Imaging in Radiation Oncology},
year = {2025},
volume = {33},
pages = {100696},
doi = {10.1016/j.phro.2025.100696}
}
EUVIMED